RoboSense Market Share Ranks 1st in China, 2nd Worldwide: Yole 2021 Global LiDAR Industry Report
23.9.2021 15:30:00 EEST | Business Wire | Press release
RoboSense LiDAR, the leading Smart LiDAR Sensor provider, boasts 10 percent of the market share worldwide, ranking first in China and second globally, according to the “LiDAR for Automotive and Industrial Applications Report 2021” from Yole Développement, an international market research and strategic consultancy. The report covers the market share of automotive and industrial applications of over ten leading LiDAR companies worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210923005530/en/
LiDAR design wins*-RoboSense boasts 10% of the market share worldwide, ranking 1st in China and 2nd globally (Photo: Business Wire)
RoboSense has been designated as an official long-term partner for many auto companies, and receiving orders for its RS-LiDAR-M1 (M1), RoboSense’s second-generation solid-state LiDAR, for a diverse range of mass-produced models since July 2020. These orders cover traditional automobile manufacturers and a supercar brand. Among them, GAC-Aion officially announced its plans to equip multiple models with RoboSense LiDAR in July this year.
The report also noted that mechanical LiDAR systems, including rotary and rotating mirror systems, have been losing market share since 2020 due to cost and reliability issues. It goes on to state that second-generation MEMS Smart LiDAR systems are entering the mainstream as its technology matures and cost gets more competitive.
World's first mass-produced automotive-grade solid-state LiDAR
RoboSense’s M1 employs advanced MEMS technologies. Launched in 2016 and with a demo prototype on the way next year, M1 was first shown at the International Consumer Electronics Show (CES) in 2018 and won two CES Innovation Awards in 2019 and 2020.
With over five years of research and dozens of upgrades, M1 became the first product to have a mass-production version finalized. RoboSense began mass-produced automotive-grade production of M1 in Q2 2021, and has since delivered over ten batches for models through its long-term automobile manufacturer partnerships.
Exclusive smart “GAZE” functionalities
M1 boasts an exclusive smart functionality named “GAZE”, which dynamically improves resolution and frame rate based on the environment, enabling vehicles to zoom in and out and augmenting their perception.
M1 enhances central resolution and extends the range of identification from 150 to 200 meters on highways, so that the vehicle can detect distant road conditions earlier. On city roads, M1 increases the frame rate from 10Hz to 20Hz and scans obstacles – such as pedestrians, electric bicycles and traffic jams – at a higher frequency for stronger near-field detection.
A multi-sensor, LiDAR-centric solution is key for accuracy and detection safety, whose reliability is known as the first step towards safe smart mobility. As Chinese LiDAR companies continue making breakthroughs in the global march towards smart mobility, RoboSense has become a leader in China and will continue in its commitment to innovate and supply the global intelligent automotive value chain with LiDAR solutions, accelerating the evolution of smart mobility.
About Yole Développement ( www.yole.fr ）
Yole Développement provides market research, technology analysis, strategy consulting, targeted media, and financial advisory services. With a strong focus on emerging applications using silicon and/or micro manufacturing since 1998, Yole Développement has expanded to include more than 80 collaborators worldwide.
About RoboSense (www.robosense.ai):
RoboSense (Suteng Innovation Technology Co., Ltd.) is a world-leading provider of Smart LiDAR Sensor Systems. Comprising LiDAR sensors, AI algorithms and IC chipsets, its portfolio transforms conventional 3D LiDAR sensors with comprehensive data analysis and interpretation systems. The company's mission is to innovate outstanding hardware and artificial intelligence capabilities to create smart solutions that enable robots, including vehicles, to have perception capabilities superior to humans.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210923005530/en/
Contact information
Grace Ye
RoboSense PR Manager
grace.ye@robosense.cn
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom